Details of the Drug Combination

General Information of Drug Combination (ID: DCKOM02)

Drug Combination Name
Hepzato PMID28870136-Compound-43
Indication
Disease Entry Status REF
Colon carcinoma Investigative [1]
Component Drugs Hepzato   DM2AZPP PMID28870136-Compound-43   DMWGV8N
N.A. Small molecular drug
High-throughput Screening Result Testing Cell Line: KM12
Zero Interaction Potency (ZIP) Score: 4.99
Bliss Independence Score: 8.28
Loewe Additivity Score: 2.18
LHighest Single Agent (HSA) Score: 2.05

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of Hepzato
Disease Entry ICD 11 Status REF
Uveal Melanoma 2D0Y Phase 3 [2]
PMID28870136-Compound-43 Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Ecto-5'-nucleotidase (CD73) TTK0O6Y 5NTD_HUMAN Inhibitor [3]
------------------------------------------------------------------------------------

Test Results of This Drug Combination in Other Disease Systems

Indication DrugCom ID Cell Line Status REF
Anaplastic large cell lymphoma DCFWGID SR Investigative [4]
Adenocarcinoma DCHR577 A549 Investigative [5]
Adenocarcinoma DC6KIMC SW-620 Investigative [5]
Adenocarcinoma DCV6U9T HT29 Investigative [5]
Malignant melanoma DC7UA4S LOX IMVI Investigative [5]
------------------------------------------------------------------------------------

References

1 Biologically active neutrophil chemokine pattern in tonsillitis.Clin Exp Immunol. 2004 Mar;135(3):511-8. doi: 10.1111/j.1365-2249.2003.02390.x.
2 ClinicalTrials.gov (NCT05022901) An Open-Label Expanded Access Study of the Melphalan/Hepatic Delivery System (HDS) in Patients With Hepatic Dominant Ocular Melanoma. U.S.National Institutes of Health.
3 Ectonucleotidase inhibitors: a patent review (2011-2016).Expert Opin Ther Pat. 2017 Dec;27(12):1291-1304.
4 Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
5 Loss of function mutations in VARS encoding cytoplasmic valyl-tRNA synthetase cause microcephaly, seizures, and progressive cerebral atrophy.Hum Genet. 2018 Apr;137(4):293-303. doi: 10.1007/s00439-018-1882-3. Epub 2018 Apr 24.